All stock lists
Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
Healthcare · Biotechnology
6.59+0.32 (+5.10%)
Insider Score
––Not scored
BOLT Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
BOLT analyst forecast
Best analysts covering BOLT
- HC Wainwright & Co.14%success rate · 7 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
BOLT analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-13 |
| — | Lake Street | Buy | — | — | Reiterated | 2025-08-15 |
| — | Stifel | Hold | — | — | Reiterated | 2025-05-13 |
| — | Stifel | Hold | — | — | Reiterated | 2025-03-25 |
| — | HC Wainwright & Co. | Neutral | — | — | Reiterated | 2025-03-25 |
| — | HC Wainwright & Co. | Neutral | — | — | Downgraded | 2024-05-15 |
| — | Jones Trading | Hold | — | — | Downgraded | 2024-05-15 |
| — | Leerink Partners | Market Perform | — | — | Downgraded | 2024-05-15 |
| — | Stifel | Hold | — | — | Downgraded | 2024-05-15 |
| — | Guggenheim | Neutral | — | — | Downgraded | 2024-05-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-22 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-06-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-05-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-05-12 |
| — | SVB Leerink | Outperform | — | — | Upgraded | 2023-05-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-03-30 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2023-01-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-10-04 |
| — | SVB Leerink | Market Perform | — | — | Downgraded | 2022-08-11 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-05-17 |
| — | Morgan Stanley | Equal Weight | — | — | Downgraded | 2022-01-06 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2021-11-10 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2021-08-16 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2021-05-17 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2021-04-06 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2021-03-02 |
| — | SVB Leerink | Outperform | — | — | Reiterated | 2021-03-02 |
| — | Stifel | Buy | — | — | Reiterated | 2021-03-02 |
BOLT earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-12 | -4.30 | -3.84 | $667K | $2.5M |
| 2026-05-12 | -2.85 | -4.31 | $1.5M | $26K |
| 2026-08-11 | -3.39 | -4.57 | $500K | $5K |
| 2026-11-11 | -3.69 | 0.00 | $426K | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.